Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HCW Biologics (HCWB) Non-Current Assets (2020 - 2025)

HCW Biologics (HCWB) has disclosed Non-Current Assets for 6 consecutive years, with $23.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non-Current Assets fell 2.47% year-over-year to $23.9 million, compared with a TTM value of $98.8 million through Sep 2025, up 3.75%, and an annual FY2024 reading of $24.5 million, up 10.98% over the prior year.
  • Non-Current Assets was $23.9 million for Q3 2025 at HCW Biologics, down from $26.0 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $26.0 million in Q2 2025 and bottomed at $3.0 million in Q2 2021.
  • Average Non-Current Assets over 5 years is $18.8 million, with a median of $21.9 million recorded in 2023.
  • The sharpest move saw Non-Current Assets surged 327.85% in 2022, then decreased 3.87% in 2023.
  • Year by year, Non-Current Assets stood at $13.0 million in 2021, then dropped by 2.27% to $12.7 million in 2022, then surged by 73.57% to $22.1 million in 2023, then grew by 10.98% to $24.5 million in 2024, then fell by 2.78% to $23.9 million in 2025.
  • Business Quant data shows Non-Current Assets for HCWB at $23.9 million in Q3 2025, $26.0 million in Q2 2025, and $24.4 million in Q1 2025.